Understanding the Synergistic Potential of Combining Claudin 18.2-Targeted Therapies with Immunotherapies
Time: 11:45 am
day: Conference Day 1
Details:
- Examining the rationale for combining Claudin 18.2-targeted therapies with immunotherapies, such as checkpoint inhibitors, to enhance anti-tumor immune responses
- Exploring preclinical and clinical data supporting combination strategies, focusing on the synergistic effects and improved therapeutic outcomes
- Reviewing the impact of combination therapies on efficacy and safety profiles, including strategies to manage immune-related adverse events
